Abstract
Monoclonal antibodies (MAbs) have been used as therapeutic agents for many years. In 1997, Rituxan® (IDEC-C2B8, rituximab, MabThera®) became the first MAb to be approved by the FDA for a cancer indication. Rituxan served to heighten interest in the therapeutic applications of MAbs. Herceptin® (for patients with breast cancer) and Mylotarg™ (for patients with acute myeloid leukemia) were approved shortly thereafter. Literally dozens of antibodies are currently under investigation for a variety of malignant and non-neoplastic indications. Rituxan is effective in patients with low-grade or follicular, relapsed or refractory non-Hodgkins lymphoma (NHL). The response rate and time to progression (responders) are in the 50% and 13 months range, respectively. It is also active in intermediate-grade NHL where a large randomized study, in combination with CHOP chemotherapy, has shown a statistically significant increase in complete response (CR) rate (75% vs. 60%), prolongation of 1 year event-free survival (69% vs. 49%) and of overall survival (83% vs. 68%) as compared to CHOP alone. This marks the first time that any agent has shown results superior to CHOP, the curative gold standard for this type of NHL. Other promising antibodies under clinical investigation include: Hu1D10; Anti CD19, 22, 52, and anti-Id antibodies. The safety profile, clinical activity, and mechanism of action of these MAbs make them ideal candidates for combination with chemotherapy or biologicals. Over the next few years, we will see very significant therapeutic advances emerge as this important research yields additional clinical results.
Current Pharmaceutical Biotechnology
Title: Monoclonal Antibodies: A New Era in the Treatment of Non-Hodgkins Lymphoma
Volume: 2 Issue: 4
Author(s): A. J. Grillo-Lopez, B.K. Dallaire, A. McClure, R. Weaver, C. Varns, A. Wei, R. Allen, D. Lee, D. Shen, J. Leonard, P.Multani and C.A.White
Affiliation:
Abstract: Monoclonal antibodies (MAbs) have been used as therapeutic agents for many years. In 1997, Rituxan® (IDEC-C2B8, rituximab, MabThera®) became the first MAb to be approved by the FDA for a cancer indication. Rituxan served to heighten interest in the therapeutic applications of MAbs. Herceptin® (for patients with breast cancer) and Mylotarg™ (for patients with acute myeloid leukemia) were approved shortly thereafter. Literally dozens of antibodies are currently under investigation for a variety of malignant and non-neoplastic indications. Rituxan is effective in patients with low-grade or follicular, relapsed or refractory non-Hodgkins lymphoma (NHL). The response rate and time to progression (responders) are in the 50% and 13 months range, respectively. It is also active in intermediate-grade NHL where a large randomized study, in combination with CHOP chemotherapy, has shown a statistically significant increase in complete response (CR) rate (75% vs. 60%), prolongation of 1 year event-free survival (69% vs. 49%) and of overall survival (83% vs. 68%) as compared to CHOP alone. This marks the first time that any agent has shown results superior to CHOP, the curative gold standard for this type of NHL. Other promising antibodies under clinical investigation include: Hu1D10; Anti CD19, 22, 52, and anti-Id antibodies. The safety profile, clinical activity, and mechanism of action of these MAbs make them ideal candidates for combination with chemotherapy or biologicals. Over the next few years, we will see very significant therapeutic advances emerge as this important research yields additional clinical results.
Export Options
About this article
Cite this article as:
A. J. Grillo-Lopez , B.K. Dallaire , A. McClure , R. Weaver , C. Varns , A. Wei , R. Allen , D. Lee , D. Shen , J. Leonard , P.Multani and C.A.White , Monoclonal Antibodies: A New Era in the Treatment of Non-Hodgkins Lymphoma, Current Pharmaceutical Biotechnology 2001; 2 (4) . https://dx.doi.org/10.2174/1389201013378563
DOI https://dx.doi.org/10.2174/1389201013378563 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Human ABC Transporters at blood-CNS Interfaces as Determinants of CNS Drug Penetration
Current Pharmaceutical Design Graphical Abstracts
Letters in Drug Design & Discovery Dihydrofolate Reductase as a Target for Chemotherapy in Parasites
Current Pharmaceutical Design Can we Consider Zoledronic Acid a New Antitumor Agent? Recent Evidence in Clinical Setting
Current Cancer Drug Targets Bioactive Metabolites from Pathogenic and Endophytic Fungi of Forest Trees
Current Medicinal Chemistry Cancer-associated Autoantibodies as Biomarkers for Early Detection and Prognosis is Cancer: An Update
Current Cancer Therapy Reviews Cellular and Biochemical Alterations Caused by Artificial Depletion of Glutathione
Current Enzyme Inhibition NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin
Mini-Reviews in Medicinal Chemistry The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Current Cancer Drug Targets Telomere Length Variations in Aging and Age-Related Diseases
Current Aging Science General Theory for Multiple Input-Output Perturbations in Complex Molecular Systems. 1. Linear QSPR Electronegativity Models in Physical, Organic, and Medicinal Chemistry
Current Topics in Medicinal Chemistry The Activity of Titanocene T Against Xenografted Caki-1 Tumors
Letters in Drug Design & Discovery Targeting Angiogenesis in Ovarian Carcinoma
Current Cancer Therapy Reviews Imaging Studies in Hypercalcemia
Current Medicinal Chemistry Geldanamycin, Radicicol, and Chimeric Inhibitors of the Hsp90 Nterminal ATP Binding Site
Current Topics in Medicinal Chemistry A Systematic Review of Genes Involved in the Inverse Resistance Relationship Between Cisplatin and Paclitaxel Chemotherapy: Role of BRCA1
Current Cancer Drug Targets The Functions of F-box Proteins in Regulating the Epithelial to Mesenchymal Transition
Current Pharmaceutical Design Computational Approaches for Translational Oncology: Concepts and Patents
Recent Patents on Anti-Cancer Drug Discovery Inhibition of Epithelial-mesenchymal Transition in Response to Treatment with Metformin and Y27632 in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry